The NOVUS Fund, created in partnership with Banco Português de Fomento, has invested in Bio-Marker.ai , a Portuguese company dedicated to transforming biomarker analysis through Artificial Intelligence (AI) and advanced medical technologies, ranging from data collection to biomarker identification and AI-assisted interpretation.
Bio-Marker.ai differentiates between traditional biochemical tests, such as the popular “blood panel”, and highly personalized genetic data, which represents the cutting edge of medicine.
Bio-Marker.ai anticipates that future advances in medicine will combine the use of classic biomarkers and AI in the diagnosis, evaluation and treatment of various diseases, such as in the case of cancer.
The company is investigating various innovations based on harnessing advances in diagnostic and monitoring technologies, together with world-class data science (AI), to create new digital health solutions.
This investment falls within the scope of the VENTURE CAPITAL programme by Banco Português de Fomento, designed to foster the growth of companies with scalable business models and strong sector potential. Under the NOVUS Fund, this objective is pursued through investments in technology-driven solutions that make use of Artificial Intelligence.
